A5064014897- Ovarian cancer diagnosis and treatment
- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- CRISPR and Genetic Engineering
- PARP inhibition in cancer therapy
- Virus-based gene therapy research
- Endometrial and Cervical Cancer Treatments
- Cancer Genomics and Diagnostics
- BRCA gene mutations in cancer
- Diversity and Career in Medicine
- Genetic factors in colorectal cancer
- Advances in Oncology and Radiotherapy
- Animal Virus Infections Studies
- Cancer Risks and Factors
- Heart Rate Variability and Autonomic Control
- Health and Medical Research Impacts
- Economic and Financial Impacts of Cancer
- Surgical Simulation and Training
- Blood Pressure and Hypertension Studies
- Hospital Admissions and Outcomes
- Colorectal and Anal Carcinomas
- Reproductive Biology and Fertility
- Surgical site infection prevention
- Pressure Ulcer Prevention and Management
- Intraperitoneal and Appendiceal Malignancies
Icahn School of Medicine at Mount Sinai
2017-2025
Mount Sinai Hospital
2025
Tisch Hospital
2025
Gynecologic Oncology Group
2023-2024
Woman's Cancer Foundation
2023
New York University
2017
Chirurgische Universitätsklinik Heidelberg
2014
Heidelberg University
2014
University Hospital Heidelberg
2014
AT&T (United States)
1987
Immunotherapy and chemotherapy combinations have shown activity in endometrial cancer, with greater benefit mismatch repair (MMR)-deficient (dMMR) than MMR-proficient (pMMR) disease. Adding a poly(ADP-ribose) polymerase inhibitor may improve outcomes, especially pMMR
Abstract Ovarian cancer has a devastating impact. In 2024 it is estimated that there will be 19,680 new ovarian diagnoses and 12,740 fatalities in the United States. Despite advancements treatment options, 80% of tumors recur or progress through treatments leading to five year survival rate just 50%. To address this unmet need, we employed functional genomics approach identify specific drug sensitivities. Comparing impact each 117 drugs our library across 32 cell lines from 11 tumor lineages...
Background Perturbation of the mechanistic target rapamycin (mTOR) pathway can instruct effector versus memory cell fate tumor antigen-specific T cells in preclinical models. In this study, we sought to understand impact (sirolimus), an mTOR inhibitor, on reprogramming vaccine-induced enhance responses patients with solid tumors following completion their standard therapy. Methods We conducted three phase I clinical trials employing New York esophageal squamous carcinoma-1 (NY-ESO-1)...
Ovarian cancer has a devastating impact. In 2024 it is estimated that there will be 19,680 new ovarian diagnoses and 12,740 fatalities in the United States. Despite advancements treatment options, 80% of tumors recur or progress through treatments leading to five year survival rate just 50%. To address this unmet need, we employed functional genomics approach identify specific drug sensitivities. Comparing impact each 117 drugs our library across 32 cell lines from 11 tumor lineages...
Abstract Background Postdischarge nausea and vomiting after ambulatory surgery is a common problem that not adequately addressed in current practice. This prospective, randomized, double-blind, parallel-group, placebo-controlled study was designed to test the hypothesis oral olanzapine superior placebo at preventing postdischarge vomiting. Methods In single-center, trial, authors compared single preoperative dose of 10 mg placebo, adult female patients 50 years old or less, undergoing...
ABSTRACT The rapidly increasing use of automatic devices for the measurement blood pressure has made it increasingly important to identify artifactual readings. This paper describes an objective technique isolating a small but adjustable percentage readings that are likely artifacts. validity these requires subjective judgment clinician. proposed methodology substantially reduces number be manually examined by not only taking into account level systolic and diastolic per se, also...
Huh, Warner K. MD; Valea, Fidel A. Chalas, Eva Blank, Stephanie V. MD Author Information
5595 Background: DUO-E (NCT04269200) showed statistically significant, clinically meaningful improvement in progression-free survival (PFS) with addition of durvalumab to CP, followed by ± the PARP inhibitor olaparib, vs CP alone for patients (pts) EC (Westin SN et al. J Clin Oncol 2024;42:283–99). inhibitors are an established approach targeting tumors homologous recombination deficiency, so we performed post hoc exploratory analyses PFS BRCAm status. Methods: Pts newly diagnosed FIGO Stage...
Objective: The bulboclitoris (clitoris and vestibular bulbs) is the primary organ responsible for female sexual arousal orgasm. Effects of radiotherapy on are unknown, as its structure/function has yet to be described in radiotherapy, it overlaps only partially with external genitalia structure. Our aim was to: describe structure, function delineation; compare volume dose delivered vs genitalia; and, bulboclitoris-sparing IMRT (BCS-IMRT) standard (S-IMRT) determine reoptimization...
<p>PFS by treatment arm according to TMB status (stratified approach, disease stage, and ECOG PS). A, TMB-low population. B, TMB-high CPB, paclitaxel, carboplatin, bevacizumab.</p>
<p>Mutations in A, BRCA1 but not B, BRCA2, are associated with PD-L1-positive tumors.</p>
<p>CCNE1 amplifications are mutually exclusive with BRCA1 and BRCA2 mutations.</p>
<div>AbstractPurpose:<p>To explore whether patients with <i>BRCA1/2</i>-mutated or homologous recombination deficient (HRD) ovarian cancers benefitted from atezolizumab in the phase III IMagyn050 (NCT03038100) trial.</p>Patients and Methods:<p>Patients newly diagnosed cancer were randomized to either placebo standard chemotherapy bevacizumab. Programmed death-ligand 1 (PD-L1) status of tumor-infiltrating immune cells (IC) was determined centrally (VENTANA...
<p>CCNE1 amplifications are mutually exclusive with BRCA1 and BRCA2 mutations.</p>